Smith BD - Search Results

1

Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.

Knorr KL, Finn LE, Smith BD, Hess AD, Foran JM, Karp JE, Kaufmann SH. Knorr KL, et al. Among authors: smith bd. Stem Cells Transl Med. 2017 Mar;6(3):840-850. doi: 10.5966/sctm.2016-0034. Epub 2016 Nov 7. Stem Cells Transl Med. 2017. PMID: 28297583 Free PMC article.

2

Inhibited apoptosis and drug resistance in acute myeloid leukaemia.

Smith BD, Bambach BJ, Vala MS, Barber JP, Enger C, Brodsky RA, Burke PJ, Gore SD, Jones RJ. Smith BD, et al. Br J Haematol. 1998 Sep;102(4):1042-9. doi: 10.1046/j.1365-2141.1998.00854.x. Br J Haematol. 1998. PMID: 9734656 Free article.

3

BP1, a new homeobox gene, is frequently expressed in acute leukemias.

Haga SB, Fu S, Karp JE, Ross DD, Williams DM, Hankins WD, Behm F, Ruscetti FW, Chang M, Smith BD, Becton D, Raimondi SC, Berg PE. Haga SB, et al. Among authors: smith bd. Leukemia. 2000 Nov;14(11):1867-75. doi: 10.1038/sj.leu.2401912. Leukemia. 2000. PMID: 11069021

4

Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia.

Brodsky RA, Sensenbrenner LL, Smith BD, Dorr D, Seaman PJ, Lee SM, Karp JE, Brodsky I, Jones RJ. Brodsky RA, et al. Among authors: smith bd. Ann Intern Med. 2001 Oct 2;135(7):477-83. doi: 10.7326/0003-4819-135-7-200110020-00006. Ann Intern Med. 2001. PMID: 11578150 Clinical Trial.

5

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.

Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D. Levis M, et al. Among authors: smith bd. Blood. 2002 Jun 1;99(11):3885-91. doi: 10.1182/blood.v99.11.3885. Blood. 2002. PMID: 12010785 Free article.

6

Response to 'comparison of "sequential" versus "standard" chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial'.

Smith BD, Karp J, Burke P. Smith BD, et al. Br J Haematol. 2003 Jul;122(1):164-5. doi: 10.1046/j.1365-2141.2003.04395_5.x. Br J Haematol. 2003. PMID: 12823362 Free article. No abstract available.

7

Ribonucleotide reductase: an old target with new potential.

Smith BD, Karp JE. Smith BD, et al. Leuk Res. 2003 Dec;27(12):1075-6. doi: 10.1016/s0145-2126(03)00248-0. Leuk Res. 2003. PMID: 12921942 No abstract available.

8

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.

Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SJ, Dai NT, Heldebrant MP, Vroman BT, Smith BD, Karp JE, Eyck CJ, Erlichman C, Kaufmann SH, Karnitz LM. Mesa RA, et al. Among authors: smith bd. Blood. 2005 Jul 1;106(1):318-27. doi: 10.1182/blood-2004-09-3523. Epub 2005 Mar 22. Blood. 2005. PMID: 15784732 Free PMC article.

9

Trying to improve clinical outcome in AML: lessons from negative trials.

Karp JE, Smith BD. Karp JE, et al. Among authors: smith bd. Leuk Res. 2005 Jun;29(6):603-4. doi: 10.1016/j.leukres.2004.12.013. Epub 2005 Mar 16. Leuk Res. 2005. PMID: 15863196 No abstract available.

10

Curing acute myelogenous leukemia: still a major challenge.

Smith BD, Karp JE. Smith BD, et al. Leuk Res. 2005 Jun;29(6):607-8. doi: 10.1016/j.leukres.2004.11.026. Epub 2005 Mar 29. Leuk Res. 2005. PMID: 15863198 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,101 results

Search Page